Green M K, Clunie G J
Transplantation. 1979 Nov;28(5):368-71. doi: 10.1097/00007890-197911000-00004.
The leucocyte migration inhibition test has been studied in a series of 192 renal allograft recipients. Seventy-seven patients showed no evidence of inhibition in the early post-transplant course, but 31 of these demonstrated clinical evidence of rejection, a false-negative rate of 16%. The remaining 115 recipients all demonstrated inhibition, with 13 of these showing no clinical evidence of rejection, a false-positive rate of 6.7%. Early antirejection therapy on the basis of inhibition did not result in improved kidney survival when compared with those recipients who did not receive specific therapy until there was clinical evidence of rejection. The leucocyte migration inhibition test did not detect changes attributable to humoral factors, which probably accounts for the high false-negative rate, and has not proved to be sufficiently reliable to be of value clinically as a single test. A combination of tests designed to detect both humoral and cellular factors responsible for rejection deserves further study.
对192例肾移植受者进行了白细胞移动抑制试验。77例患者在移植后早期无抑制证据，但其中31例出现排斥反应的临床证据，假阴性率为16%。其余115例受者均表现出抑制，其中13例无排斥反应的临床证据，假阳性率为6.7%。与那些直到出现排斥反应的临床证据才接受特异性治疗的受者相比，基于抑制进行早期抗排斥治疗并未改善肾脏存活率。白细胞移动抑制试验未检测到由体液因素引起的变化，这可能是导致高假阴性率的原因，而且尚未证明作为单一试验在临床上足够可靠而有价值。旨在检测导致排斥反应的体液和细胞因素的联合试验值得进一步研究。
